Plasminogen activator inhibitor-1 (PAI-1) has important regulatory functions in haemostasis, extracellular matrix turn-over and cell adhesion. We studied PAI-1 gene expression in primary cultures of endometrial stromal cells, and found that PAI-1 protein and mRNA were increased both by agents associated with differentiation, i.e. progesterone and transforming growth factor β 1 (TGFβ 1 ), and by those promoting proliferation, i.e. epidermal growth factor (EGF), TGFα and basic fibroblast growth factor (bFGF). In order to further elucidate the mechanism of regulation, we transfected stromal cells with an expression construct containing 804 bp of the PAI-1 promoter fused to a chloramphenicol acetyl transferase (CAT) reporter gene. After stimulation with the polypeptide growth factors TGFβ1, EGF and bFGF we found increased CAT activity, indicating that these stimulators had initiated interaction with the transfected promoter fragment. On the other hand, stimulation with progesterone did not increase CAT activity, even though these cells were perfectly able to respond with increased secretion of PAI-1 protein. Run off experiments demonstrated that progesterone increased the stability of PAI-1 mRNA in endometrial stromal cells. We conclude that the polypeptide growth factors TGFβ 1 , EGF and bFGF increase PAI-1 expression by increasing gene transcription. Progesterone, on the other hand, does not interact with the 804 bp promoter region, but increases the stability of PAI-1 mRNA.
Introduction
Plasminogen activator inhibitor-1 (PAI-1) is an important regulator of pericellular proteolysis (Loskutoff, 1991) . It is the specific inhibitor of both urokinase plasminogen activator (u-PA), which is involved in degradation of extracellular matrix, and tissue plasminogen activator (t-PA), which is involved in fibrinolysis and thrombolysis (Hart and Rehemtulla, 1988; Danø et al., 1994) . Both activators catalyse conversion of the zymogen plasminogen to active plasmin, a proteolytic enzyme with a broad spectrum of extracellular substrates.
The human endometrium is a dynamic tissue which proliferates rapidly after menstruation under the influence of oestrogen, and differentiates after ovulation under the influence of progesterone. Endometrial growth in the proliferative phase, which is remarkably rapid for a normal adult tissue, is accompanied by high PA activity (Casslén and Ohlsson, 1981; Casslén and Å stedt, 1981) . In contrast, differentiation in the secretory phase requires low PA activity to prepare the endometrium for implantation of the blastocyst. In particular, endometrial haemostasis and extracellular matrix accumulation has high priority during this period. Since PAI-1 is the main inhibitor of the PA system, its regulation is crucial to the balance of endometrial proteolysis. Increased expression of PAI-1 in endometrial cells seems to be a direct effect of progesterone action (Casslén et al., 1992 (Casslén et al., , 1995 Chen et al., 1992; Schatz et al., 1993) . However, many other effects of gonadal steroids in the endometrium are mediated via paracrine mechanisms. Growth factors, which have been shown to induce PAI-1 in other cell types, include transforming growth factor β (TGFβ), epidermal growth factor (EGF), transforming growth factor α (TGFα) and basic fibroblast growth factor (bFGF) (Laiho and KeskiOja, 1989; Andreasen et al., 1990) . All these growth factors have been identified in the human endometrium (Rusnati et al., 1990; Chegini et al., 1992; Gold et al., 1994) .
TGFβ is a family of three closely related homodimers, TGFβ 1-3 , which are associated with tissue differentiation, accumulation of extracellular matrix, and induction of PAI-1 in a variety of cell-types (Laiho and Keski-Oja, 1989; Andreasen et al., 1990; Massagué, 1990) . EGF has been reported to influence the PA-system in human endometrial cells (Miyauchi et al., 1995) . Stimulation with EGF and TGFα, which also binds to the EGF receptor, interacts with the signalling pathway of oestradiol in the mouse uterus, i.e. oestrogen induces mRNA and protein for both EGF and its receptor, the effects of EGF/ TGFα mimick those of oestrogen, and an oestrogen receptor antagonist attenuates the effect of EGF (Nelson et al., 1991; Ignar-Trowbridge et al., 1992) . bFGF is a potent stimulator of proliferation and u-PA expression in endothelial cells, and the migratory response to bFGF in these cells is in fact mediated by the increase of u-PA (Odekon et al., 1992) . It is present in the human endometrial epithelium as well as in the stroma (Gold et al., 1994) .
In this study, we examined the regulation of PAI-1 gene expression by TGFβ 1 , EGF, bFGF and progesterone in primary cultures of human endometrial stromal cells.
Endometrial tissue
Endometrial tissue was obtained from hysterectomy specimens or at diagnostic curretage due to benign non-endometrial pathology, e.g. cervical dysplasia, dysmenorrhoea, uterine prolapse, and fibromyomas. All patients were parous, 25-45 years of age, and menstruating regularly. Permission to use part of the endometrium was granted by the University Review Board for studies on human subjects. Histopathological examination of the formalin-fixed portion excluded pathology of the endometrium.
Tissue collection, processing and culture All endometrial samples were collected under sterile conditions. At hysterectomy endometrial tissue was scraped from the upper part of the uterine cavity, which had been exposed by an incision in the anterior wall immediately after removal of the uterus. Separation of the endometrial tissue in epithelial and stromal cells was performed as previously described (Casslén et al., 1990) . Briefly, the tissue was transferred to a dissociation solution, cut in 1 mm 3 pieces and incubated at 37°C in a shaking waterbath for 45-60 min.
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Dissociation solution contained collagenase 2.5 g/l, DNase 0.2 g/l, and TLCK 0.2 µM in HBSS. After digestion, the suspension was filtered through a 350 µm nylon mesh to remove undigested fragments, and the cell suspension was further passed through a 35 µm nylon mesh. The stromal cells were retrieved by centrifuging at 1200 g for 5 min, resuspended in culture medium, and plated at a concentration of 100 000 cells/well. The cultures were rinsed with HBSS after 1 day, and the experiment started when the cultures were confluent. Purity of the stromal cell cultures was 96-99%, when analysed with immunocytochemistry using antibodies to vimentin and cytokeratin (Casslén et al., 1995) .
Medium M199, supplemented with 10% FBS, glutamine 2 mM, penicillin 100 000 IU/l, streptomycin 100 mg/l and Fungizone 0.25 mg/l was used for all cultures. Phenol Red was omitted from HBSS and M199 to avoid interference with the steroid receptors. Steroids were dissolved in ethanol, and stock solutions of 1000 and 10 000 times the final concentration were used in order to keep the final concentration of ethanol ഛ0.1%. The following concentrations of stimulants were used throughout: TGFβ 1 10 ng/ml, EGF 10 ng/ml, bFGF 10 ng/ml, oestradiol 10 nmol/l and progesterone 100 nmol/l. Cultures were incubated in humidified air with 5% CO 2 at 37°C. During the experiments, conditioned media were harvested daily, replaced by 0.5 ml fresh media and stimulants added. Collected media were kept at -20°C until assay.
Immunoassay for PAI-1 PAI-1 protein was measured in a commercial enzyme-linked immunosorbent assay (ELISA) kit (Imulyse™PAI-1; Biopool, Umeå, Sweden), which detected the active and latent forms of PAI-1, as well as PAI-1 in complex with PAs.
RNA analysis
Total RNA was prepared from stromal cell pellets using the RNeasy™ total RNA purification kit. RNA aliquots (5-10 µg) were size separated on 1% agarose gels containing 2.2 M formaldehyde. The RNA was then transferred to Gene Screen Plus nylon filters (Thomas, 1980) . The probes were radiolabelled with [ 32 P]-dCTP using the random labelling method Megaprime DNA labelling systems (Feinberg and Vogelstein, 1984) . The filters were hybridized in 0.25 M sodium phosphate, 7% SDS, 1 mM EDTA at 65°C for 12 h. After hybridization, the filters were washed in 0.02 M sodium phosphate, 1% SDS for 3ϫ10 min at 65°C. Autoradiography was performed for 1-12 h and signal intensities were measured by densitometry on a Bio Image computer system. All filters were hybridized to the probes for PAI-1 and also, in order to verify equal loading, to a human β-actin cDNA probe.
Transfection assay
Cells were grown on gelatin-coated Petri dishes in Medium 199 without Phenol Red supplemented by 10% FBS, 2 mM glutamine, 1 nM oestradiol. Cell cultures were passaged 24 h before transfection, and the subconfluent cultures received fresh medium 2-4 h before transfection. The procedure was initiated by 6 h incubation of the cells with calcium phosphate-precipitated DNAs (15 µg plasmid per 90 mm dish). Following a 2 min 15% (v/v) glycerol shock (Sambrook et al., 1989) , fresh medium with stimulants was added. The culture medium was changed every 24 h, and conditioned media were stored at -70°C for PAI-1 antigen analysis. Cells were harvested for transient expression 72 h later. pRSV-βgal (Promega) was co-transfected as an internal control. Chloramphenicol acetyl transferase (CAT) assay was performed using a Quan-T-CAT assay system (Amersham). β-gal activity was measured using a Promega β-galactosidase enzyme assay system as recommended by the manufacturer. A -804 to ϩ17 fragment Figure 1 . Concentrations of plasminogen activator inhibitor-1 (PAI-1) in conditioned medium of endometrial stromal cell cultures (n ϭ 12) which had been treated for 2 days with either ethanol as control (C), oestradiol 10 nM (E), oestradiol 10 nM ϩ progesterone 100 nM (EP), transforming growth factor (TGF)β 1 10 ng/ml, epidermal growth factor (EGF) 10 ng/ml, TGFα 10 ng/ml or basic fibroblast growth factor (bFGF) 10 ng/ml. Results are expressed as mean Ϯ SEM. Concentrations of PAI-1 were increased by EP (P ϭ 0.003), TGFβ 1 (P ϭ 0.002), EGF (P ϭ 0.002), TGFα (P ϭ 0.003) and bFGF (P ϭ 0.002).
of the PAI-1 promoter region of the 4G type coupled to a CAT gene (pCAT-Basic, Promega) was constructed as described earlier (Riccio et al., 1988; Eriksson et al., 1995) . No progesterone binding sites have so far been described in the human PAI-1 promoter.
Statistical analysis
Results are expressed as mean Ϯ SEM. The significance of differences between groups was calculated using the Wilcoxon signed rank test. All tests were two-sided, and P Ͻ 0.005 was considered to be significant.
Results
Confluent cultures of human endometrial stromal cells released PAI-1 protein at low basal concentrations. The release was not increased by oestradiol alone, but by a combination of oestradiol and progesterone (Figure 1 ). Also the polypeptide growth factors TGFβ 1 , EGF, TGFα and bFGF increased release of PAI-1 into the conditioned medium. Since EGF and TGFα induced PAI-1 secretion to a similar extent, and both growth factors act through the EGF receptor, further experiments included only EGF. Cellular content of PAI-1 mRNA relative to β-actin mRNA was calculated in Northern blots after treatment of stromal cells with oestradiol, oestradiol plus progesterone, TGFβ 1 , EGF or bFGF. All these agents increased the cellular contents of PAI-1 mRNA (Figure 2 ). PAI-1 mRNA was increased in a time-dependent way by treatment with progesterone ϩ oestradiol or TGFβ 1 , but not by oestradiol alone (Figure 3) .
In order to investigate whether these effects could be mediated by transcriptional activation, an assay was established using endometrial cells which had been transfected with an Figure 2 . The amount of plasminogen activator inhibitor-1 (PAI-1) mRNA relative to that of β-actin (mean of two experiments) was calculated by densimetric scanning of autoradiograms. Endometrial stromal cell cultures had been stimulated for 2 days with either ethanol for control (C), oestradiol 10 nM (E), oestradiol 10 nM ϩ progesterone 100 nM (EP), transforming growth factor (TGF )β 1 10 ng/ml, epidermal growth factor (EGF) 10 ng/ml, or basic fibroblast growth factor (bFGF) 10 ng/ml. IOD ϭ integrated optical density.
804 bp fragment of the human PAI-1 promoter coupled to a chloramphenicol acetyl transferase (CAT) gene. EGF, bFGF or TGFβ 1 significantly increased activity of the PAI-1 promoter, whereas progesterone had no such effect (Figures 4 and 5) . The secretion of PAI-1 protein was, however, enhanced by progesterone to the same extent in the transfected cells as in non-transfected stromal cells ( Figure 6B,C) . This finding suggests that the observed effect of progesterone on the amount of PAI-1 mRNA was not mediated by activation of the PAI-1 gene promoter, at least not within the region we studied.
Since stimulation with progesterone increased the cellular content of PAI-1 mRNA, but did not increase secreted CATactivity in transfected cells, we explored the possibility that progesterone influenced the mRNA stability. Confluent stromal cell cultures, which had been stimulated with either oestradiol or oestradiol and progesterone, were incubated with actinomycin D, an inhibitor of transcription. The content of PAI-1 mRNA, assayed after 1 and 2 h, was reduced by 40% in oestradiol stimulated cultures, but remained unchanged at the starting concentration in progesterone-treated cultures ( Figure  7 ). This finding strongly suggests increased stability of the PAI-1 mRNA in progesterone-treated cultures.
Discussion
In the present study we have shown that the polypeptide growth factors TGFβ 1 , EGF/TGFα and bFGF enhance both PAI-1 protein secretion, PAI-1 mRNA concentrations and PAI-1 promoter activity in human endometrial stromal cells, suggesting that these factors mediate transcriptional activation of the PAI-1 promoter. This explains, at least in part, the growth factor-enhanced PAI-I protein secretion from the endometrial cells. Regions of the PAI-1 promoter that respond to Figure 3 . Plasminogen activator inhibitor-1 (PAI-1) mRNA was demonstrated in Northern blots of total RNA extracts from endometrial stromal cell cultures, which had been stimulated by 10 nM oestradiol (E), 10 nM oestradiol ϩ 100 nM progesterone (EP), 10 ng/ml of transforming growth factor (TGF)β 1 or ethanol for control (C). A representative blot shows the two size-separated transcripts of PAI-1 mRNA (upper panel). The amount of specific PAI-1 mRNA (mean of two experiments) was calculated relative to the amount of β-actin mRNA by densitometric scanning of autoradiograms. PAI-1 mRNA increased in a time dependent way in response to TGFβ 1 and EP, whereas oestradiol had no effect (lower panel).
TGFβ in the human hepatoma cell lines HepG2 and Hep3B have been extensively analysed and shown to reside within the region of the probe used in our transfection assay (Westerhausen et al., 1991; Riccio et al., 1992) . It is, therefore, likely that TGFβ mediates its response in a similar fashion and through the same promoter elements in the endometrial cells. Activation of the PAI-1 promoter by bFGF and EGF has not been studied in detail in other cell systems. Thus it remains to be shown which promoter element and what transcription factor(s) are involved in the activation process.
The mechanism whereby progesterone induces PAI-1 secretion is less clear. An observation in our laboratory, that the effects of TGFβ 1 and progesterone were additive, suggested that these agents operate through different mechanisms (B.Casslén, T.Sandberg, B.Gustavsson, R.Willén and M.Nilbert, unpublished results). The lack of induction of the 804 bp fragment of the PAI-1 promoter in the transfection assay suggests that no progesterone response elements reside within this region. However, ligand-bound progesterone receptor binds to the same DNA elements as the glucocorticoid receptor (Martinez and Wahli, 1991) and it has been reported that glucocorticoids induce increased PAI-1 mRNA values (Andreasen et al., 1987) . Furthermore, transfection studies using a promoter fragment Figure 4 . Primary cultures of endometrial stromal cells were transfected with a -804 to ϩ17 fragment of the plasminogen activator inhibitor-1 (PAI-1) promoter coupled to a CAT gene, and stimulated by (A) 1 or 10 ng/ml epidermal growth factor (EGF) or (B) 1 or 10 ng/ml basic fibroblast growth factor (bFGF). Results are expressed as mean Ϯ SEM and are based on four (EGF) and three (bFGF) experiments performed in duplicate. Chloramphenicol acetyl transferase (CAT) activity was increased by 1 ng/ml (P Ͻ 0.05) and 10 ng/ml EGF (P Ͻ 0.05), and 10 ng/ml bFGF (P Ͻ 0.05). similar to that used in this study have demonstrated a glucocorticoid-induced transcription of PAI-1 in the human fibrosarcoma cell line HT-1080 (Riccio et al., 1988) . Putative glucocorticoid response elements are located in this promoter fragment but no extensive functional analysis of these sites has been performed. The lack of progesterone activation of the PAI-1 promoter in endometrial stromal cells, while enhancing PAI-1 protein secretion and the amount of PAI-1 mRNA, suggests that the progesterone effect is not mediated through the putative glucocorticoid response elements within the probe used in these experiments. Although it cannot be excluded that the progesterone-receptor complex potentially interacts with other response elements outside the 804 bp fragment of the PAI-1 promoter, our data suggest that progesterone mediates an enhanced stability of the PAI-1 transcripts. Stabilization of mRNA is reportedly involved in induction of the PAI-1 gene in HepG2 cells by insulin, insulin-like growth factor 1 (Fattal et al., 1992) and VLDL (Sironi et al., 1996) . It remains to be shown whether progesterone and these additional compounds enhance PAI-1 mRNA stability through the same or different mechanisms.
The finding that PAI-1 gene expression is regulated by both progesterone and a variety of growth factors in endometrial cells stresses the importance of this inhibitor in balancing the different requirements for proteolytic activity which subsist during proliferation, differentiation and desquamation of endometrial tissue. A shift from rapid turnover of extracellular matrix proteins in the proliferative phase to their accumulation in the secretory phase is initiated by progesterone after ovula- tion (Farrar and Carson, 1992; Zhu et al., 1992) , and requires extensive modulation of the proteolytic activity. In this context, PAI-1 is a central molecule, being an inhibitor of both fibrinolysis and extracellular matrix degradation. Additional functions, not related to the inhibition of u-PA and t-PA, have in fact been described for PAI-1. Thus, PAI-1 in complex with vitronectin is also an inhibitor of thrombin, and vitronectin mediates cellular binding and internalization of the thrombin/ PAI-1 complex (Preissner et al., 1996) . Furthermore, PAI-1 influences adhesion of cells to their substratum by competing with the u-PA receptor for the somatomedin B binding site in vitronectin (Deng et al., 1996) . We have previously reported that PAI-1 protein and mRNA are up-regulated by progesterone and DH-testosterone in cultured endometrial stromal cells (Casslén et al., 1992) , and that upregulation of PAI-1 contributes to the accelerated degradation of u-PA by these cells (Casslén et al., 1995) . This study has shown that TGFβ 1 , EGF/TGFα and bFGF also stimulate PAI-1 protein and mRNA. The fact that both 'mitogenic factors' like EGF and bFGF and 'differentiating factors' like TGFβ 1 and progesterone stimulate expression of PAI-1, can be taken to indicate that PAI-1 has a function to balance proteolytic activity in multiple processes during the endometrial cycle.
Both the ovarian steroids, oestradiol and progesterone, initiate a network of paracrine mechanisms involving growth factors as well as cytokines in the endometrial tissue. Furthermore, as has been shown in the murine uterus, oestradiol interacts with the intracellular signalling mechanism of EGF/TGFα, probably at the level of oestrogen response elements in the promoter region of oestrogen-sensitive genes (Nelson et al., 1991; Ignar-Trowbridge et al., 1995) . Such interactions with growth factors have, however, not been reported for progesterone. Also, our results do not suggest interactions between progesterone and growth factors in the PAI-1 gene promoter.
Endometrial tissue is stimulated to commence rapid growth under the influence of oestrogen in the proliferative phase. This effect is at least partly mediated by EGF, and also oestradiol stimulates expression of EGF receptors (Lingham 786 et al., 1988; Nelson et al., 1991) . Our finding that EGF increases the expression of PAI-1, presumably reflects a need for PAI-activity to provide a proteolytic balance also in the proliferative phase when higher PA-activity is required.
bFGF is known as an angiogenic factor. The migratory response of endothelial cells to bFGF is, however, mediated by increased secretion of u-PA, and its subsequent binding to the cell surface receptor (Odekon et al., 1992) . bFGF, which is a potent stimulator of both u-PA (T. Sandberg, B. Classlén, unpublished data) and PAI-1 in endometrial stromal cells, is equally expressed in proliferative and secretory endometria (Rusnati et al., 1990; Gold et al., 1994) . However, increased amounts of bFGF in post-menopausal endometria may indicate a negative regulation by oestradiol and progesterone, and suggest increased amounts in menstrual endometria as well. Induction of PAI-1 in endometrial stromal cells by bFGF and/ or TGFβ 1 during endometrial angiogenesis may serve to attenuate u-PA activity in growing capillary endothelial cells.
